Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temozolomide or Dacarbazine-based Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor

Trial Profile

Temozolomide or Dacarbazine-based Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs Endostatin (Primary) ; Temozolomide (Primary) ; Dacarbazine; Fluorouracil
  • Indications Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2018 Primary endpoint (Overall response rate) has been met, according to the results published in the Medicine
    • 01 Nov 2018 Results published in the Medicine
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top